fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

ICYMI: FAH/AHA Drug Pricing Study Continues to Make Headlines

January 11, 2017 | FAH Policy Blog Team

Category: FAH News, Media, Pharmaceuticals

The website Healthcare Dive recently refocused the spotlight on the FAH/AHA hospital drug pricing study by publishing a feature article entitled, “How hospitals can fight the cost of budget-busting drugs.”

Reporters Ana Mulero and Lisa LaMotta used the FAH/AHA study as a basis to highlight rapidly rising hospital drug costs and what can be done to make sure it doesn’t harm patient care.

As the story states, the report found that, “High increases had either a moderate or severe impact on more than 90% of the budgets of hospitals surveyed.”

FAH CEO Chip Kahn told the reporters the goal was to raise the visibility of the issue and inform policy makers.

"We had been hearing from hospital leaders about the fix they were in regarding generic drugs or pre-FDA drugs," Kahn told Healthcare Dive. "Because of what was happening with the ownership and licensure of those drugs companies like Valeant basically had a monopoly on some of these drugs…In hundreds of cases, there have been thousands of percent increases in drugs — antibiotics and others."

The article also examines what hospitals can do to lessen the impact on their budgets. Steps that include:

  • Look for a generic or branded generic alternative for drugs that have undergone unexpected price increases.
  • Substitute combination drugs, when possible, with their respective components.

Healthcare Dive also looked at how the drug industry is responding to the controversy and what the federal government might do to resolve the problem.

You can read the entire article here.